[1] Petosemtamab granted Breakthrough Therapy Designation bythe U.S. FDA. Retrieved May 13, 2024 from https://ir.merus.nl/news-releases/news-release-details/petosemtamab-granted-breakthrough-therapy-designation-us-fda
[2] Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecificantibody targeting EGFR and LGR5, in advanced head and neck squamous cellcarcinoma (HNSCC). Retrieved May 13, 2024 from https://merus.nl/wp-content/uploads/2023/04/CT012_Cohen_AACR-2023_Oral_Peto-HNSCC_11Apr2023.pdf
[3] Corporate Presentation. Retrieved May 13, 2024 from https://ir.merus.nl/static-files/909329a7-7cf3-44c4-878b-ae9bf61ce711